Texas SB3005 mandates a study on psychedelic therapies for post-traumatic stress disorder, depression, and other conditions.
Texas SB3005 directs the Department of State Health Services to conduct a comprehensive study on the use of psychedelic therapies, specifically MDMA, psilocybin, and ketamine, for treating post-traumatic stress disorder, depression, and other co-occurring conditions. The study will review clinical trials, current literature, FDA actions, and treatment guidelines.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.